Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgPro20 long-term extension study in CIDP
NL-OMON44389Phase 3Active, not recruiting
- Sponsor
- CSL Limited
- Start
- Mar 2015
- Countries
- 1
01
Overview
Phase 3, open-label trial of polyvalent human immunoglobulin in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by CSL Limited. Primary endpoint: Overall rate of adverse events per infusion. Started Mar 2015; status: active, not recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON44389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44389.